GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PolyPeptide Group AG (XSWX:PPGN) » Definitions » EV-to-EBIT

PolyPeptide Group AG (XSWX:PPGN) EV-to-EBIT : -21.92 (As of May. 20, 2024)


View and export this data going back to 2021. Start your Free Trial

What is PolyPeptide Group AG EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PolyPeptide Group AG's Enterprise Value is CHF1,112.3 Mil. PolyPeptide Group AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-50.7 Mil. Therefore, PolyPeptide Group AG's EV-to-EBIT for today is -21.92.

The historical rank and industry rank for PolyPeptide Group AG's EV-to-EBIT or its related term are showing as below:

XSWX:PPGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.4   Med: 56.3   Max: 97
Current: -21.92

During the past 6 years, the highest EV-to-EBIT of PolyPeptide Group AG was 97.00. The lowest was -22.40. And the median was 56.30.

XSWX:PPGN's EV-to-EBIT is ranked worse than
100% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.86 vs XSWX:PPGN: -21.92

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. PolyPeptide Group AG's Enterprise Value for the quarter that ended in Dec. 2023 was CHF594.6 Mil. PolyPeptide Group AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-50.7 Mil. PolyPeptide Group AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -8.53%.


PolyPeptide Group AG EV-to-EBIT Historical Data

The historical data trend for PolyPeptide Group AG's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPeptide Group AG EV-to-EBIT Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - - 67.65 85.78 -11.98

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.65 - 85.78 - -11.98

Competitive Comparison of PolyPeptide Group AG's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PolyPeptide Group AG's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PolyPeptide Group AG's EV-to-EBIT falls into.



PolyPeptide Group AG EV-to-EBIT Calculation

PolyPeptide Group AG's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1112.270/-50.742
=-21.92

PolyPeptide Group AG's current Enterprise Value is CHF1,112.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PolyPeptide Group AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-50.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PolyPeptide Group AG  (XSWX:PPGN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

PolyPeptide Group AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-50.742/594.55964
=-8.53 %

PolyPeptide Group AG's Enterprise Value for the quarter that ended in Dec. 2023 was CHF594.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PolyPeptide Group AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-50.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PolyPeptide Group AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of PolyPeptide Group AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


PolyPeptide Group AG (XSWX:PPGN) Business Description

Traded in Other Exchanges
Address
Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives a majority of its revenue from Europe and Asia.

PolyPeptide Group AG (XSWX:PPGN) Headlines

No Headlines